Introduction 14
What is this report about? 14
Who is the target reader? 14
How to use this report 14
Definitions 14
Group of Eight (G8) Generics 15
Industry Outlook 15
Generics in Canada 19
Market Overview 19
Market Data 20
Market Segmentation 22
Market outlook 23
Five forces analysis 25
Macroeconomic indicators 32
Generics in France 34
Market Overview 34
Market Data 35
Market Segmentation 37
Market outlook 38
Five forces analysis 40
Macroeconomic indicators 46
Generics in Germany 48
Market Overview 48
Market Data 49
Market Segmentation 51
Market outlook 52
Five forces analysis 54
Macroeconomic indicators 60
Generics in Italy 62
Market Overview 62
Market Data 63
Market Segmentation 65
Market outlook 66
Five forces analysis 68
Macroeconomic indicators 74
Generics in Japan 76
Market Overview 76
Market Data 77
Market Segmentation 79
Market outlook 80
Five forces analysis 82
Macroeconomic indicators 88
Generics in Russia 90
Market Overview 90
Market Data 91
Market Segmentation 93
Market outlook 94
Five forces analysis 96
Macroeconomic indicators 102
Generics in The United Kingdom 104
Market Overview 104
Market Data 105
Market Segmentation 107
Market outlook 108
Five forces analysis 110
Macroeconomic indicators 117
Generics in The United States 119
Market Overview 119
Market Data 120
Market Segmentation 122
Market outlook 123
Five forces analysis 125
Macroeconomic indicators 132
Company Profiles 134
Leading Companies 134
Appendix 174
Methodology 174
About MarketLine 175

List of Tables
Table 1: G8 generics industry, revenue($m), 2013-22
Table 2: G8 generics industry, revenue by country ($m), 2013-17
Table 3: G8 generics industry forecast, revenue by country ($m), 2017-22
Table 4: Canada generics market value: $ million, 2013-17
Table 5: Canada generics market volume: % of total pharma, 2013-17
Table 6: Canada generics market geography segmentation: $ million, 2017
Table 7: Canada generics market value forecast: $ million, 2017-22
Table 8: Canada generics market volume forecast: % of total pharma, 2017-22
Table 9: Canada size of population (million), 2013-17
Table 10: Canada gdp (constant 2005 prices, $ billion), 2013-17
Table 11: Canada gdp (current prices, $ billion), 2013-17
Table 12: Canada inflation, 2013-17
Table 13: Canada consumer price index (absolute), 2013-17
Table 14: Canada exchange rate, 2013-17
Table 15: France generics market value: $ million, 2013-17
Table 16: France generics market volume: % of total pharma, 2013-17
Table 17: France generics market geography segmentation: $ million, 2017
Table 18: France generics market value forecast: $ million, 2017-22
Table 19: France generics market volume forecast: % of total pharma, 2017-22
Table 20: France size of population (million), 2013-17
Table 21: France gdp (constant 2005 prices, $ billion), 2013-17
Table 22: France gdp (current prices, $ billion), 2013-17
Table 23: France inflation, 2013-17
Table 24: France consumer price index (absolute), 2013-17
Table 25: France exchange rate, 2013-17
Table 26: Germany generics market value: $ million, 2013-17
Table 27: Germany generics market volume: % of total pharma, 2013-17
Table 28: Germany generics market geography segmentation: $ million, 2017
Table 29: Germany generics market value forecast: $ million, 2017-22
Table 30: Germany generics market volume forecast: % of total pharma, 2017-22
Table 31: Germany size of population (million), 2013-17
Table 32: Germany gdp (constant 2005 prices, $ billion), 2013-17
Table 33: Germany gdp (current prices, $ billion), 2013-17
Table 34: Germany inflation, 2013-17
Table 35: Germany consumer price index (absolute), 2013-17
Table 36: Germany exchange rate, 2013-17
Table 37: Italy generics market value: $ million, 2013-17
Table 38: Italy generics market volume: % of total pharma, 2013-17
Table 39: Italy generics market geography segmentation: $ million, 2017
Table 40: Italy generics market value forecast: $ million, 2017-22
Table 41: Italy generics market volume forecast: % of total pharma, 2017-22
Table 42: Italy size of population (million), 2013-17
Table 43: Italy gdp (constant 2005 prices, $ billion), 2013-17
Table 44: Italy gdp (current prices, $ billion), 2013-17
Table 45: Italy inflation, 2013-17
Table 46: Italy consumer price index (absolute), 2013-17
Table 47: Italy exchange rate, 2013-17
Table 48: Japan generics market value: $ million, 2013-17
Table 49: Japan generics market volume: % of total pharma, 2013-17
Table 50: Japan generics market geography segmentation: $ million, 2017
Table 51: Japan generics market value forecast: $ million, 2017-22
Table 52: Japan generics market volume forecast: % of total pharma, 2017-22
Table 53: Japan size of population (million), 2013-17
Table 54: Japan gdp (constant 2005 prices, $ billion), 2013-17
Table 55: Japan gdp (current prices, $ billion), 2013-17
Table 56: Japan inflation, 2013-17
Table 57: Japan consumer price index (absolute), 2013-17
Table 58: Japan exchange rate, 2013-17
Table 59: Russia generics market value: $ million, 2013-17
Table 60: Russia generics market volume: % of total pharma, 2013-17
Table 61: Russia generics market geography segmentation: $ million, 2017
Table 62: Russia generics market value forecast: $ million, 2017-22
Table 63: Russia generics market volume forecast: % of total pharma, 2017-22
Table 64: Russia size of population (million), 2013-17
Table 65: Russia gdp (constant 2005 prices, $ billion), 2013-17
Table 66: Russia gdp (current prices, $ billion), 2013-17
Table 67: Russia inflation, 2013-17
Table 68: Russia consumer price index (absolute), 2013-17
Table 69: Russia exchange rate, 2013-17
Table 70: United Kingdom generics market value: $ million, 2013-17
Table 71: United Kingdom generics market volume: % of total pharma, 2013-17
Table 72: United Kingdom generics market geography segmentation: $ million, 2017
Table 73: United Kingdom generics market value forecast: $ million, 2017-22
Table 74: United Kingdom generics market volume forecast: % of total pharma, 2017-22
Table 75: United Kingdom size of population (million), 2013-17
Table 76: United Kingdom gdp (constant 2005 prices, $ billion), 2013-17
Table 77: United Kingdom gdp (current prices, $ billion), 2013-17
Table 78: United Kingdom inflation, 2013-17
Table 79: United Kingdom consumer price index (absolute), 2013-17
Table 80: United Kingdom exchange rate, 2013-17
Table 81: United States generics market value: $ billion, 2013-17
Table 82: United States generics market volume: % of total pharma, 2013-17
Table 83: United States generics market geography segmentation: $ billion, 2017
Table 84: United States generics market value forecast: $ billion, 2017-22
Table 85: United States generics market volume forecast: % of total pharma, 2017-22
Table 86: United States size of population (million), 2013-17
Table 87: United States gdp (constant 2005 prices, $ billion), 2013-17
Table 88: United States gdp (current prices, $ billion), 2013-17
Table 89: United States inflation, 2013-17
Table 90: United States consumer price index (absolute), 2013-17
Table 91: United States exchange rate, 2013-17
Table 92: Apotex, Inc.: key facts
Table 93: Mylan N.V.: key facts
Table 94: Mylan N.V.: key financials ($)
Table 95: Mylan N.V.: key financial ratios
Table 96: Novartis AG: key facts
Table 97: Novartis AG: key financials ($)
Table 98: Novartis AG: key financial ratios
Table 99: Sanofi SA: key facts
Table 100: Sanofi SA: key financials ($)
Table 101: Sanofi SA: key financials (€)
Table 102: Sanofi SA: key financial ratios
Table 103: Les Laboratoires Servier: key facts
Table 104: STADA Arzneimittel AG: key facts
Table 105: STADA Arzneimittel AG: key financials ($)
Table 106: STADA Arzneimittel AG: key financials (€)
Table 107: STADA Arzneimittel AG: key financial ratios
Table 108: Daiichi Sankyo Co Ltd: key facts
Table 109: Daiichi Sankyo Co Ltd: key financials ($)
Table 110: Daiichi Sankyo Co Ltd: key financials (¥)
Table 111: Daiichi Sankyo Co Ltd: key financial ratios
Table 112: Lupin Ltd: key facts
Table 113: Lupin Ltd: key financials ($)
Table 114: Lupin Ltd: key financials (Rs.)
Table 115: Lupin Ltd: key financial ratios
Table 116: Sawai Pharmaceutical Co Ltd: key facts
Table 117: Sawai Pharmaceutical Co Ltd: key financials ($)
Table 118: Sawai Pharmaceutical Co Ltd: key financials (¥)
Table 119: Sawai Pharmaceutical Co Ltd: key financial ratios
Table 120: Abbott Laboratories: key facts
Table 121: Abbott Laboratories: key financials ($)
Table 122: Abbott Laboratories: key financial ratios
Table 123: Krka, d. d., Novo mesto: key facts
Table 124: Krka, d. d., Novo mesto: key financials ($)
Table 125: Krka, d. d., Novo mesto: key financials (€)
Table 126: Krka, d. d., Novo mesto: key financial ratios
Table 127: Pfizer Inc.: key facts
Table 128: Pfizer Inc.: key financials ($)
Table 129: Pfizer Inc.: key financial ratios
Table 130: Teva Pharmaceutical Industries Limited: key facts
Table 131: Teva Pharmaceutical Industries Limited: key financials ($)
Table 132: Teva Pharmaceutical Industries Limited: key financial ratios

List of Figures
Figure 1: G8 generics industry, revenue($m), 2013-22
Figure 2: G8 Generics industry, revenue by country (%), 2017
Figure 3: G8 generics industry, revenue by country ($m), 2013-17
Figure 4: G8 generics industry forecast, revenue by country ($m), 2017-22
Figure 5: Canada generics market value: $ million, 2013-17
Figure 6: Canada generics market volume: % of total pharma, 2013-17
Figure 7: Canada generics market geography segmentation: % share, by value, 2017
Figure 8: Canada generics market value forecast: $ million, 2017-22
Figure 9: Canada generics market volume forecast: % of total pharma, 2017-22
Figure 10: Forces driving competition in the generics market in Canada, 2017
Figure 11: Drivers of buyer power in the generics market in Canada, 2017
Figure 12: Drivers of supplier power in the generics market in Canada, 2017
Figure 13: Factors influencing the likelihood of new entrants in the generics market in Canada, 2017
Figure 14: Factors influencing the threat of substitutes in the generics market in Canada, 2017
Figure 15: Drivers of degree of rivalry in the generics market in Canada, 2017
Figure 16: France generics market value: $ million, 2013-17
Figure 17: France generics market volume: % of total pharma, 2013-17
Figure 18: France generics market geography segmentation: % share, by value, 2017
Figure 19: France generics market value forecast: $ million, 2017-22
Figure 20: France generics market volume forecast: % of total pharma, 2017-22
Figure 21: Forces driving competition in the generics market in France, 2017
Figure 22: Drivers of buyer power in the generics market in France, 2017
Figure 23: Drivers of supplier power in the generics market in France, 2017
Figure 24: Factors influencing the likelihood of new entrants in the generics market in France, 2017
Figure 25: Factors influencing the threat of substitutes in the generics market in France, 2017
Figure 26: Drivers of degree of rivalry in the generics market in France, 2017
Figure 27: Germany generics market value: $ million, 2013-17
Figure 28: Germany generics market volume: % of total pharma, 2013-17
Figure 29: Germany generics market geography segmentation: % share, by value, 2017
Figure 30: Germany generics market value forecast: $ million, 2017-22
Figure 31: Germany generics market volume forecast: % of total pharma, 2017-22
Figure 32: Forces driving competition in the generics market in Germany, 2017
Figure 33: Drivers of buyer power in the generics market in Germany, 2017
Figure 34: Drivers of supplier power in the generics market in Germany, 2017
Figure 35: Factors influencing the likelihood of new entrants in the generics market in Germany, 2017
Figure 36: Factors influencing the threat of substitutes in the generics market in Germany, 2017
Figure 37: Drivers of degree of rivalry in the generics market in Germany, 2017
Figure 38: Italy generics market value: $ million, 2013-17
Figure 39: Italy generics market volume: % of total pharma, 2013-17
Figure 40: Italy generics market geography segmentation: % share, by value, 2017
Figure 41: Italy generics market value forecast: $ million, 2017-22
Figure 42: Italy generics market volume forecast: % of total pharma, 2017-22
Figure 43: Forces driving competition in the generics market in Italy, 2017
Figure 44: Drivers of buyer power in the generics market in Italy, 2017
Figure 45: Drivers of supplier power in the generics market in Italy, 2017
Figure 46: Factors influencing the likelihood of new entrants in the generics market in Italy, 2017
Figure 47: Factors influencing the threat of substitutes in the generics market in Italy, 2017
Figure 48: Drivers of degree of rivalry in the generics market in Italy, 2017
Figure 49: Japan generics market value: $ million, 2013-17
Figure 50: Japan generics market volume: % of total pharma, 2013-17
Figure 51: Japan generics market geography segmentation: % share, by value, 2017
Figure 52: Japan generics market value forecast: $ million, 2017-22
Figure 53: Japan generics market volume forecast: % of total pharma, 2017-22
Figure 54: Forces driving competition in the generics market in Japan, 2017
Figure 55: Drivers of buyer power in the generics market in Japan, 2017
Figure 56: Drivers of supplier power in the generics market in Japan, 2017
Figure 57: Factors influencing the likelihood of new entrants in the generics market in Japan, 2017
Figure 58: Factors influencing the threat of substitutes in the generics market in Japan, 2017
Figure 59: Drivers of degree of rivalry in the generics market in Japan, 2017
Figure 60: Russia generics market value: $ million, 2013-17
Figure 61: Russia generics market volume: % of total pharma, 2013-17
Figure 62: Russia generics market geography segmentation: % share, by value, 2017
Figure 63: Russia generics market value forecast: $ million, 2017-22
Figure 64: Russia generics market volume forecast: % of total pharma, 2017-22
Figure 65: Forces driving competition in the generics market in Russia, 2017
Figure 66: Drivers of buyer power in the generics market in Russia, 2017
Figure 67: Drivers of supplier power in the generics market in Russia, 2017
Figure 68: Factors influencing the likelihood of new entrants in the generics market in Russia, 2017
Figure 69: Factors influencing the threat of substitutes in the generics market in Russia, 2017
Figure 70: Drivers of degree of rivalry in the generics market in Russia, 2017
Figure 71: United Kingdom generics market value: $ million, 2013-17
Figure 72: United Kingdom generics market volume: % of total pharma, 2013-17
Figure 73: United Kingdom generics market geography segmentation: % share, by value, 2017
Figure 74: United Kingdom generics market value forecast: $ million, 2017-22
Figure 75: United Kingdom generics market volume forecast: % of total pharma, 2017-22
Figure 76: Forces driving competition in the generics market in the United Kingdom, 2017
Figure 77: Drivers of buyer power in the generics market in the United Kingdom, 2017
Figure 78: Drivers of supplier power in the generics market in the United Kingdom, 2017
Figure 79: Factors influencing the likelihood of new entrants in the generics market in the United Kingdom, 2017
Figure 80: Factors influencing the threat of substitutes in the generics market in the United Kingdom, 2017
Figure 81: Drivers of degree of rivalry in the generics market in the United Kingdom, 2017
Figure 82: United States generics market value: $ billion, 2013-17
Figure 83: United States generics market volume: % of total pharma, 2013-17
Figure 84: United States generics market geography segmentation: % share, by value, 2017
Figure 85: United States generics market value forecast: $ billion, 2017-22
Figure 86: United States generics market volume forecast: % of total pharma, 2017-22
Figure 87: Forces driving competition in the generics market in the United States, 2017
Figure 88: Drivers of buyer power in the generics market in the United States, 2017
Figure 89: Drivers of supplier power in the generics market in the United States, 2017
Figure 90: Factors influencing the likelihood of new entrants in the generics market in the United States, 2017
Figure 91: Factors influencing the threat of substitutes in the generics market in the United States, 2017
Figure 92: Drivers of degree of rivalry in the generics market in the United States, 2017
Figure 93: Mylan N.V.: revenues & profitability
Figure 94: Mylan N.V.: assets & liabilities
Figure 95: Novartis AG: revenues & profitability
Figure 96: Novartis AG: assets & liabilities
Figure 97: Sanofi SA: revenues & profitability
Figure 98: Sanofi SA: assets & liabilities
Figure 99: STADA Arzneimittel AG: revenues & profitability
Figure 100: STADA Arzneimittel AG: assets & liabilities
Figure 101: Daiichi Sankyo Co Ltd: revenues & profitability
Figure 102: Daiichi Sankyo Co Ltd: assets & liabilities
Figure 103: Lupin Ltd: revenues & profitability
Figure 104: Lupin Ltd: assets & liabilities
Figure 105: Sawai Pharmaceutical Co Ltd: revenues & profitability
Figure 106: Sawai Pharmaceutical Co Ltd: assets & liabilities
Figure 107: Abbott Laboratories: revenues & profitability
Figure 108: Abbott Laboratories: assets & liabilities
Figure 109: Krka, d. d., Novo mesto: revenues & profitability
Figure 110: Krka, d. d., Novo mesto: assets & liabilities
Figure 111: Pfizer Inc.: revenues & profitability
Figure 112: Pfizer Inc.: assets & liabilities
Figure 113: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 114: Teva Pharmaceutical Industries Limited: assets & liabilities